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Simple Summary: This review analyses the complex involvement of the various components of the
endocannabinoid system (ECS) in the susceptibility to cancer, prognosis, and response to treatment,
focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal,
gynaecological, prostate cancer, thoracic, thyroid, central nervous system (CNS) tumours,
and melanoma). The same ECS component can exert both protective and pathogenic effects in
different tumour subtypes, which are often pathologically driven by different biological factors.
Although an attractive target in cancer, the use of components in anti-cancer treatment is still
interlinked with many legal and ethical issues that need to be considered. The legislation which
outlines the permissive boundaries of their therapeutic use in oncology is still unable to follow the
current scientific burden of evidence, but the number of ongoing clinical trials might tip the scale
forward in the near future.
Abstract: The various components of the endocannabinoid system (ECS), such as the cannabinoid
receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in
several tumour-related states, both as favourable and unfavourable factors. This review analyses
the ECS’s complex involvement in the susceptibility to cancer, prognosis, and response to treatment,
focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal,
gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma). Changes in the
expression and activation of CBRs, as well as their ability to form distinct functional heteromers
affect the cell’s tumourigenic potential and their signalling properties, leading to pharmacologically
different outcomes. Thus, the same ECS component can exert both protective and pathogenic effects
in different tumour subtypes, which are often pathologically driven by different biological factors.
The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of effects
they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity),
depend in great deal on the tumour type and the specific ECS component that they target. Although
an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many
legal and ethical issues that need to be considered.
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1. Introduction
Historically, cannabinoids have primarily been used as palliative care agents in oncology.
However, the various components of the endocannabinoid system (ECS), such as the cannabinoid
receptors (CBRs), cannabinoid ligands, and their signalling network are interlinked with several
tumour-related states, both as favourable and unfavourable factors. This vast network of molecules
is an attractive pharmacological target, and its full potential is yet to be reached. Understanding the
specific ways ECS components can regulate the cell cycle, proliferation and cell death considering
their interactions with the immune system is necessary for advancing the current state of the art
in cannabinoid-based anti-cancer therapeutic approaches. This review analyses the ECS’s complex
involvement in the susceptibility to cancer, prognosis and response to treatment, focusing on its
relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological,
prostate cancer, thoracic, thyroid, CNS tumours, and melanoma).
2. The Interplay between Cancer Biology and the Endocannabinoid System
So far, seven receptors that respond to endogenous and exogenous cannabinoid ligands in humans
have been described in literature [1], namely the main cannabinoid receptors 1 and 2 (CB1R, coded
by CNR1 gene [2] and CB2R, coded by CNR2 gene [3]), as well as G protein-coupled receptors 18
(N-arachidonyl glycine receptor, GPR18 [4]), 55 (GPR55 [5]) and 119 (Glucose-dependent insulinotropic
receptor, GPR119 [6]) and the transient receptor potential cation channel subfamily V members 1 and 2
(TRPV1 [7], TRPV2 [8]). All these receptors might be useful anti-cancer targets individually, as well as in
various heteromerization scenarios. A simple STRING analysis [9], showed that cannabinoid receptors
CB1R and CB2R directly interact with each other using several evidence platforms, as well with GPR18,
GPR55 and TRPV1 (Figure 1a). Additional cluster analysis extended to five primary-interaction shell
genes showed that GPR119 is only indirectly connected with the other receptors while TRPV2 seems
to form a separate network entity (Figure 1b). The extended network is enriched in interactions
(PPI enrichment p-value: 2.39 × 10−12), meaning that these seven receptors in general interact more
than is expected for a random set of molecules of similar size and can be considered, at least partially,
as a biologically connected group [9].
Changes in expression and activation of these CBRs, as well as their ability to form distinct
functional heteromers with many other receptors alter the cell’s tumuorigenic potential and their
signalling properties, leading to pharmacologically different outcomes upon their stimulation [10–12].
Thus, the same ECS component can exert both protective and pathogenic effects in different tumour
subtypes, which are often pathologically driven by different biological factors.
Cannabinoid receptors are widely expressed on normal and cancer cells. The interactive
open-access databases the Human Protein Atlas [13,14] and UALCAN [15,16] were used to analyse the
Cancer Genome Atlas (TCGA) [17] transcriptome data and assess their expression in various cancer
subtypes. In silico analyses showed that cannabinoid receptors were generally not prognostically
significant, but are enriched (mostly at the RNA level where more data is available) in some cancer
subtypes: CNR1 in glioma (Figure 2a), CNR2 in testicular cancer (Figure 2b), GPR119 in pancreatic
cancer, where it is also a favourable prognostic factor (p < 0.001, Figure 2c [18]) and TRPV2 in melanoma,
while it is an unfavourable prognostic factor in renal (p < 0.001, Figure 2d [19]) and testicular cancer
(p < 0.001, Figure 2e [20]).
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Figure 1. STRING i tion analysis of c n abinoid receptors. (a) Direct STRING analysis
network was uilt based on high onfidence (0.7) evid nc from exp ime tal interaction data
(pink), co-expression (black), gene neighbourhood (green) and co-occurrence (blue) data, curated
databases (light blue), protein homology (purple), and predictive and knowledge text mining
(light green); (b) The network was extended to 5 primary-interaction shell genes to explore
their indirect interactions and clustering (PPI enrichment p-value: 2.39 × 10−12) using the
intersection of 12 genes present on all analysed platforms. Red nodes—CNR1/CNR2 cluster, green
nodes—GPR119 cluster, blue nodes—TRPV2 cluster. Nodes are labelled with Human Gene Nomenclature
Committee (HGNC) gene symbols: CNR1—Cannabinoid receptor 1 gene, CNR2—Cannabinoid
receptor 2 gene, DRD2—dopamine receptor D2, DRD3—dopamine receptor D3, GCG—glucagon,
GPR18—N-arachidonyl glycine receptor (G-protein coupled receptor 18), GPR55—G-protein coupled
receptor 55, GPR119—Glucose-dependent insulinotropic receptor (G protein-coupled receptor 119),
OPRD1—Opioid Receptor Delta 1, OPRL1—Opioid Related Nociceptin Receptor 1, TRPV1 and
TRPV2—transient receptor potential cation channel subfamily V members 1 and 2.
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Figure 2. The expression of CNR1, CNR2, 119 and TRPV2 in cancer according to the Human
Protein Atlas database [13]. (a) Expression of CNR1 in cancer subtypes; (b) expression of CNR2 in
cancer subtypes; (c) survival curves of pancreatic cancer patients according to the expression of GPR119
favourable prognostic factor, p < 0.001); (d) survival curves of renal cancer patients according to the
expression of TRPV2 (unfavourable prognostic factor, p < 0.001); (e) survival curves of testicular cancer
according to the expression of TRPV2 (unfavourable prognostic factor, p < 0.001).
The receptors are also significantly over- or under-expressed in some cancer subtypes compared
to normal tissue which might be useful for diagnostics and specific anti-cancer approaches
(Table 1) [16]. Interestingly, all cannabinoid receptors were found to be significantly under-expressed
in colon adenocarcinoma.
Cancers 2020, 12, 3275 4 of 21
Table 1. Comparison of cannabinoid receptors’ genetic expression in normal vs. tumour tissue according to the UALCAN database [16] analysis of TCGA data.
Cancer Type Receptor Cancer Subtype Expression in Tumour vs. Normal Tissue p Value
Breast cancer CNR1 Breast invasive carcinoma Under-expressed 7.09 × 10−11
CNR2 Breast invasive carcinoma Under-expressed 1.55 × 10−2
GPR18 Breast invasive carcinoma Over-expressed 3.60 × 10−7
Gastrointestinal malignancies CNR1 Cholangiocarcinoma Over-expressed 3.16 × 10−2
Colon adenocarcinoma Under-expressed 1.58 × 10−7
Hepatocellular carcinoma Over-expressed 3.52 × 10−11
Rectum adenocarcinoma Under-expressed 9.80 × 10−3
CNR2 Colon adenocarcinoma Under-expressed 6.57 × 10−4
Rectum adenocarcinoma Under-expressed 2.83 × 10−2
GPR18 Colon adenocarcinoma Under-expressed 3.30 × 10−6
GPR55 Colon adenocarcinoma Under-expressed 2.16 × 10−4
GPR119 Colon adenocarcinoma Under-expressed 1.55 × 10−5
Hepatocellular carcinoma Under-expressed 3.58 × 10−5
Pancreatic adenocarcinoma Over-expressed 1.73 × 10−2
Rectum adenocarcinoma Under-expressed 2.84 × 10−3
TRPV1 Hepatocellular carcinoma Over-expressed 4.75 × 10−6
Stomach adenocarcinoma Over-expressed 1.32 × 10−3
TRPV2 Cholangiocarcinoma Over-expressed 5.71 × 10−7
Hepatocellular carcinoma Over-expressed 4.27 × 10−9
Stomach adenocarcinoma Over-expressed 1.22 × 10−8
Gynaecological malignancies CNR1 Uterine corpus endometrial carcinoma Under-expressed 1.54 × 10−2
GPR18 Cervical squamous cell carcinoma Over-expressed 1.18 × 10−3
GPR55 Cervical squamous cell carcinoma Over-expressed 1.64 × 10−9
Uterine corpus endometrial carcinoma Under-expressed 9.88 × 10−7
Prostate cancer CNR1 Prostate adenocarcinoma Under-expressed 3.45 × 10−6
TRPV1 Prostate adenocarcinoma Over-expressed 1.05 × 10−4
TRPV2 Prostate adenocarcinoma Under-expressed 3.56 × 10−2
Thoracic tumours CNR1 Lung adenocarcinoma Under-expressed 1.62 × 10−12
Lung squamocellular carcinoma Under-expressed 4.06 × 10−7
TRPV1 Lung adenocarcinoma Over-expressed <1 × 10−12
Lung squamous cell carcinoma Over-expressed 6.11 × 10−10
TRPV2 Lung adenocarcinoma Under-expressed <1 × 10−12
Lung squamous cell carcinoma Under-expressed 1.62 × 10−12
Thyroid cancer CNR1 Thyroid carcinoma Under-expressed 3.05 × 10−2
CNR2 Thyroid carcinoma Under-expressed 1.72 × 10−5
GPR18 Thyroid carcinoma Under-expressed 3.94 × 10−3
GPR55 Thyroid carcinoma Over-expressed 2.24 × 10−4
TRPV1 Thyroid carcinoma Under-expressed 3.74 × 10−2
Central nervous system malignancies GPR18 Glioblastoma multiforme Over-expressed 1.60 × 10−6
TRPV1 Glioblastoma multiforme Under-expressed 4.78 × 10−2
Melanoma (primary vs. metastasis) CNR2 Skin cutaneous melanoma Over-expressed 1.22 × 10−6
GPR18 Skin cutaneous melanoma Over-expressed 1.61 × 10−9
GPR119 Skin cutaneous melanoma Under-expressed 1.95 × 10−2
TRPV2 Skin cutaneous melanoma Under-expressed 3.81 × 10−2
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2.1. Breast Cancer
Breast cancer (BC) remains the most common malignant disease in women in Western countries.
Although the rates of mortality have declined since the late 1990s primarily due to adjuvant systemic
therapy and earlier detection by palpation and mammograms, some breast tumours remain resistant
to conventional therapies. In addition, actual treatments have side effects that substantially affect
the patients’ quality of life [21–24] and many plants have been evaluated as supplementary and
alternative anticancer medicines [25,26]. As BC is a highly heterogeneous disease in terms of molecular
portraits, prognosis, and treatment [23], there are three main BC subtypes based on classical molecular
profiles: hormone receptor-positive, Human epidermal growth factor receptor 2 (HER2)-positive, and
triple-negative tumours. The current state-of-the art suggests that cannabinoid-based approaches may
offer a therapeutic benefit in these three BC subtypes [27].
2.1.1. Cannabinoids and Hormone-Sensitive Breast Cancer
The presence of estrogen receptors (ER) and/or progesterone receptors (PR) in BC cells defines a
subgroup of breast tumours that may be susceptible to endocrine therapy. Specifically, patients are
treated surgically and/or pharmacologically employing the blockage of estrogenic signalling, which
has pro-proliferative features. Targeted strategies either remove the endogenous source of estrogens
and/or employ selective ER modulators, such as tamoxifen or inhibitors of aromatase, the main enzyme
responsible for estrogen synthesis [24]. It has been demonstrated that cannabinoids modulate pivotal
tumour progression-related aspects of ER+/PR+ BC cells. The endocannabinoid anandamide exerts its
anti-proliferative action by blocking the cell cycle progression [28] and by inhibiting adenylyl cyclase
thus activating the Raf-1/ERK/MAPK cascade [28–30]. This effect is mediated by the activation of
CB1R [28–30] and is not accompanied by cancer cell death [28]. The proliferation of the ER-/PR+ human
BC cell line EVSA-T also decreased in response to tetrahydrocannabinol (THC) [31,32]. Cannabinoids
impair ER+/PR+ cancer cell migration and invasion in vitro. The selective activation of CB2R in cells
over-expressing the chemokine receptor CXCR4 led to the inhibition of chemotaxis and wound healing
similar to the effect induced by the CXCR4 ligand CXCL1220 [27].
2.1.2. Cannabinoids and HER2-Positive Breast Cancer
Breast tumours expressing HER2 constitute another breast cancer subtype. HER2 is a member of
the epidermal growth factor receptor (EGFR) family, involved in a number of oncogenic processes as cell
proliferation and survival [33]. Around 20–30% of primary BC cells exhibit HER2 gene amplification and
protein over-expression which is a poor prognostic biomarker and leads to an unfavourable response
to chemotherapy [34]. Therapeutic outcomes have improved since the incorporation of Herceptin®
(trastuzumab, an antibody against the extracellular domain of HER2) and Tykerb® (lapatinib), a dual
EGFR/HER2 tyrosine kinase inhibitor [23,27].
At the same time, CB2R is over-expressed in BC and is present in high levels in aggressive
(high-grade) tumours [31,35,36]. The deregulation of the ECS in many cancers has been broadly
documented [27,37–39], and although there is a strong rationale for using CB2R as an anti-cancer drug
target [27,40,41], details on its impact in tumour development and progression are still lacking.
Strong preclinical evidence suggest that cannabinoids may be useful for the treatment of this
BC subtype. THC exerts a significant anti-tumour action in a model of HER2-positive metastatic
BC [42]. THC treatment reduces not only tumour growth, but also the number of generated
tumours [36]. Xenograft-based approaches have strengthened the hypothesis that HER2-overexpressing
tumours may be sensitive to treatment with THC 14 and/or CB2R-selective agonists [36,43] decreasing
tumour growth [43]. Interestingly, the activation of CB2R has been linked with anti-tumour effect of
cannabinoids in all HER2-positive BC models used [27].
The protein complexes CXCR4-CB2R, GPR55-CB2R, and HER2-CB2R have been proposed as
novel therapeutic targets for HER2+ BC. They possess particular pharmacological and signalling
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properties, and their modulation might affect the anti-tumoural activity of the ECS. Cannabinoid
receptor heteromers have a promising value as new potential targets for BC therapies and as prognostic
biomarkers [44–47].
2.1.3. Cannabinoids and Triple-Negative Breast Cancer
Triple-negative BC lacks the expression of ER, PR and HER2. There is no standard targeted
therapy for these patients, whose prognosis is very poor [21]. Attempts have been made to improve
chemotherapy responses, like the combined use of angiogenesis inhibitors as Avastin® (bevacizumab)
and poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors [21,23]. Preclinical evidence
indicates that this subtype may be treated with cannabinoids. A collection of synthetic cannabinoids
have been tested and inhibited cell proliferation [31,35,48–52]. The cannabinoids, via CB1 and/or CB2
receptors, confer a less invasive phenotype to triple negative BC, showing that these compounds may
have a reduced cancer cell metastatic potential in vivo [35]. Phytocannabinoids other than THC have
also shown anti-tumour actions in BC. Cannabidiol (CBD) has low affinity for CB1R and CB2R [53]
and is emerging as an attractive drug in many conditions, although its detailed mechanism of action
has still not been elucidated [54,55]. It has been shown that CBD impacts not only proliferation but
also metastasis-related capability [27,50,51].
Although there is a high evidence load suggesting the anti-tumour effects of cannabinoids in BC,
there have also been reports of their pro-tumourigenic effects [27,56–58].
2.2. Gastrointestinal Malignancies
Gastrointestinal cancers (GIC) represent a vast family of malignant diseases including rectal cancer,
biliary cancer, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, anal cancer,
early colon cancer, familial risk colorectal cancer, and hepatocellular carcinoma. Standard treatment
approaches depend on various clinical and genetic factors and are constantly evolving to meet the
patients’ needs. Despite all invested efforts, colorectal cancer (CRC) is still the third most common
malignant disease in the world with around 1.8 million new cases in 2018, and in second place by
mortality induced by cancer with around 0.9 million deaths [59]. The ECS’s involvement in the
development, progression and treatment of CRC has been evaluated in terms of the implication of
cannabinoid receptors, endo- and synthetic cannabinoids, as well as various ECS-induces signalling
molecules [60,61].
The expression of CB2R is a poor prognostic factor in CRC and its activation via the
AKT/GSK3β signalling pathway has been linked with a more aggressive phenotype [62]. On the
other side, the down-regulation of CB1R has been linked with metastatic CRC [63]. Endogenous
and synthetic cannabinoids elicit the suppression of CRC cells proliferation and migration and
stimulate apoptosis, via receptor-dependent and independent mechanisms [64]. The intracellular
pathways include inhibition of RAS–MAPK and PI3K–AKT axis, cell cycle arrest, down-regulation of
anti-apoptotic proteins, increased ceramide synthesis, activation of caspases etc. It has previously been
shown that traditional phytocannabinoids (THC or CBD) have slightly lower anti-cancer potency in
GIC than synthetic compounds, like the CBD derivative HU-331 and CP 55,940 [65,66]. The screening
of a library of synthetic cannabinoids led to the discovery of three families of compounds (CP 55,940,
CP 47,497, and PTI) able to reduce the viability of CRC cells in vitro [67]. As treatment with antagonists
of some CBRs (CB1R, CB2R, GPR55, and TRPV1) did not show a reduction of the activity of these drugs,
it was concluded that they might act through a non-canonical receptor mechanism. Modification of these
compounds taking into account the different anti-cancer potency of various stereoisomers is suggested
as a future direction for the development of novel therapies for CRC. Their use for potentiating the
effects of standard chemotherapeutics and in preventing adverse side effects like nausea, vomiting,
toxicity, pain and loss of appetite needs to be balanced with their known psychotropic effects [64,68].
The anti-cancer potential of the peroxisome proliferator-activated receptor γ (PPARγ) has also been
linked with its affinity towards cannabinoids such as THC and JWH-015 in hepatocellular carcinoma
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in vitro and in vivo [69]. The up-regulation of PPARγ upon cannabinoid binding is considered to have
a protective role from inflammation, oxidation, fibrosis, fatty liver and liver tumours [70].
The enzyme monoacylglycerol lipase (MAGL) involved in the metabolism of endogenous
cannabinoids is also expressed in higher levels in aggressive CRC cells [71]. Evidence exists that
MAGL might modulate angiogenesis, thus its pharmacological inhibition represents a potential new
therapeutic approach for the inhibition of CRC progression. The over-activation of the ECS in GIC is
associated with poor prognosis and advanced disease stage but reports of its down-regulation in the
metastatic setting also exist. This implies that the specific strategy for ECS exploitation in GIC strongly
depends on the tumour type and stage.
2.3. Gynecological Malignancies
Gynaecological malignancies make up approximately one out of six cancers in women [72].
Although they are usually grouped together, cancers of the female reproductive system comprise a
diverse group of cancers with distinct risk factors, signs and symptoms, clinical presentations and
treatment modalities, each named after the anatomical part in which the cancer started: cervical,
ovarian, uterine (endometrial cancer and uterine sarcoma), vaginal, vulvar, and fallopian tube [73].
Since they play important roles in the regulation of cell proliferation, differentiation and survival,
endocannabinoids (ECS) have emerged as a cell regulatory mechanism involved in protection against
cancer development. In addition, endocannabinoids are actively involved in all aspects of female
reproduction such as oocyte production [74] and their impairment has been associated with various
gynaecological pathological conditions such as ectopic pregnancies (N-arachidonoylethanolamine
(AEA), CB1R, fatty acid amide hydrolase (FAAH)) and cancer. The expression of CB1R, CB2R, N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD) and FAAH was shown in normal human
ovaries, while AEA was found in the follicular fluid after ovarian stimulation by hormones [75].
2.3.1. Endometrial Cancer (EMC)
CB2 receptors might play a pivotal role in endometrial cancer. It has been shown that CB2R
is over-expressed in endometrial cancer biopsies while it’s only weakly expressed in the adjacent
normal tissue as well as healthy endometrial tissue [76]. The same study investigated the underlying
signalling pathways showing that the complete endogenous pathway of CB2R activation is significantly
altered in EMC. They used CB2R over-expressing AN3CA cells to demonstrate a significant reduction
in cell vitality compared to parental AN3CA cells. They also showed that incubation with the
selective CB2R antagonist SR144128 was able to restore the viability of CB2R over-expressing cells.
AN3CA cells transfected with a plasmid containing cDNA for CB2R showed a 40% reduction in
mitochondrial function compared to control cells which indicated a potential role of CB2R in the
control of EMC cell growth through the modulation of mitochondrial function. Beside CB2R, the
endocannabinoid 2-arachidonoylglycerol (2-AG) is present in significantly high levels in cancerous
tissues [77]. The significant over-expression of CB2R and 2-AG might be used as a novel therapeutic
target for EMC. The expression of CB1R, AEA and palmitoylethanolamine lipid (PEA) were not
significantly different between normal and tumour tissue although AEA and PEA showed elevated
levels in EMC [76]. Statistical significance was reached in the study by Ayakanny et al. who
demonstrated that plasma and tissue AEA and PEA levels were significantly higher in EMC than in
controls [78]. Since their levels are significantly higher in plasma of EMC patients than in the healthy
controls, these biomarkers can be useful in early and non-invasive diagnosis of endometrial cancer.
2.3.2. Ovarian Cancer (OC)
It was shown that aggressive ovarian cancer cells (SKOV3) display significantly elevated MAGL
hydrolytic activity compared to non-aggressive cells (OVCAR3). MAGL degrades 2-AG which is also
found in elevated levels in high-grade primary human ovarian tumours [79]. Induced over-expression
of MAGL in non-aggressive cancer cells increases their pathogenicity. This effect is reversed by MAGL
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inhibitors which have an important therapeutic potential. GPR55 has also been investigated in OC
cell lines. High GPR55 expression on both protein and mRNA levels was shown in OVCAR2 and
A2780 OC cell lines [80]. CB1R expression was moderate in benign and borderline epithelial ovarian
tumours but it was strongly increased in invasive ovarian tumours [81].
2.3.3. Cervical Cancer (CC)
As conventional chemotherapy has limited success in the reduction of cervical cancer (CC) mortality,
the influence of various plant-derived products in the development and treatment of this disease has
been investigated in recent years [82–84]. While investigating Cannabis sativa and the ECS in this
setting, a specific expression pattern of CB1R, CB2R, and TRPV1 in CC cell lines and tumour biopsies
was observed [85]. The investigation of the effect of AEA on CC cell lines also showed interesting
results. HeLa and CC299 cells were sensitive to AEA that induced DNA fragmentation leading to cell
cycle arrest and cell death. Interestingly, selective CB1R and CB2R antagonists enhanced the toxic
effects of AEA suggesting possible protective effect of CB1R and CB2R in AEA-induced cell death [85].
Contrary to this, TRPV1-selective antagonist capsazepine (CZ) protected cells against AEA, suggesting
that TRPV1 is involved in the mechanism of AEA-induced apoptosis in cervical cancer cell lines. In the
CC cell lines HeLa and C33A, CBD was able to decrease the invasiveness in a concentration-dependent
manner by the up-regulation of TIMP metallopeptidase inhibitor 1 (TIMP-1) via CB1R/CB2R and
TRPV1 [86]. Also, CBD-induced cell death by accumulation of cells in the sub-G0 phase which was
most likely related to caspase-9 and caspase-3 up-regulation upon CBD treatment [82]. Based on these
in vitro studies, in vivo studies should be initiated to investigate CBD as an additional therapeutic tool
in cervical cancer treatment.
2.4. Prostate Cancer (PC)
Prostate cancer is one of the most common malignant cancers in men. It is the second most
frequently diagnosed cancer and one of the leading causes of cancer death worldwide in the male
population [87]. Standard treatment of localized PC is surgery or radiotherapy. Approximately one
third of conventionally treated patients will develop metastases, at which point androgen withdrawal
is the most effective form of systemic therapy. Unfortunately, androgen deprivation is associated with
a gradual transition of PC cells through a spectrum of androgen dependence, followed by androgen
sensitivity, and finally androgen independence, known as castration-resistant prostate cancer (CRPC).
This stage of PC has a more aggressive phenotype and is unresponsive to further hormonal therapy,
with a very poor prognosis [88,89]. Cannabinoids have shown a high anticancer activity in PC, but the
specific molecular mechanisms responsible for these effects depend on the drug and tumour context.
In PC, abnormal expression of ECS has been found. This has been related to cancer prognosis,
suggesting a potential therapeutic implication of ECS in tumour progression. Anandamide levels are
elevated more than threefold [77], and CB1R and CB2R expressions are also increased in PC [90,91].
High expression of CB1R has been associated with poor prognosis. In vitro data also showed that
GPR55 is expressed in LNCaP, PC3, and DU145 prostate cancer cell lines, where it signals via calcium
mobilization and the activation of Akt and ERK1/2 [80].
Phytocannabinoids, endocannabinoids, and synthetic cannabinoids have proved to inhibit prostate
tumour cell proliferation, migration, and metastasis, as well as to induce apoptosis. Various authors
have shown endogenous 2-AG as a potential inhibitor of androgen-independent prostate cancer cells
invasion [92], by inhibiting adenylyl cyclase and reducing protein kinase A (PKA) activity, suggesting
that these effects are mediated by CB1R [92–94]. Noladin ether has also proven to inhibit the invasion
of PC cells [95]. An increase in endogenous 2-AG levels after MAGL inhibition has also been shown
to interfere with cancer progression. MAGL inhibitors lower the invasive capacity of PC and this
effect is partially reversed by the blockage of CB1R [93,94,96]. The disruption of MAGL activity
lowers EGFR expression, thus reducing the EGF-induced cell proliferation [97]. Sundry’s studies have
evidenced the anti-proliferative activity of cannabinoids in prostate tumours. Anandamide inhibits the
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proliferation of cells (PC-3, DU-145, and LNCaP) [98,99] and primary cultures of PC [91] via CB1R.
Phytocannabinoids also reduce PC cell proliferation. The two main cannabinoids from the marijuana
plant (delta-9-tetrahydrocannabinol (∆9-THC) and CBD) cause cell death in PC-3 and LNCaP PC cell
lines, respectively, inducing apoptosis in LNCaP cells [100,101]. However, the anti-proliferative activity
of CBD and ∆9-THC does not involve cannabinoid receptors. Other synthetic cannabinoids, such as
WIN-55,512-22, JWH-015, and HU-210 also exert antitumour effects in PC cells, as they inhibit cellular
proliferation in androgen-insensitive PC cell lines [30,90,93,94,102,103].
It has recently been reported that CB2R can form heteromers with the GPC chemokine receptor
CXCR4 in PC cells [44,47,104]. CXCR4 is involved in various mechanisms that enhance the cell’s ability
to proliferate and migrate, thus its activation has been linked to local and distant metastatic invasion.
This heteromerization might enable cannabinoids to indirectly reduce the invasive properties of cancer
cells by inhibiting the effects of CXCR4 agonists [44,47,104]. These data point to a novel pharmacologic
target affecting tumour cell migration and invasion that could be useful in the metastatic setting.
2.5. Thoracic Tumours
In 2018, over two million new lung cancer (LC) cases were diagnosed, and over 1.3 million people
have died from LC, making this disease the most common occurring malignant disease in the world,
as well as the most common cause of cancer-related deaths [59]. Although LC is a model cancer for
the success of molecular targeted therapies [105,106], due to the high cost of radiologically-based
nation-wide screening programs [107,108], it is most often diagnosed in advanced disease stages when
the level of cancer-related pain is high [109]. An individual combination of pharmacological and
non-pharmacological approaches for each patient ensures the optimal palliative care which results
in higher quality of life and longer survival. The role of the ECS is ambiguous in LC, as there have
been sporadic reports connecting the use of cannabinoids to a higher risk of LC [110] and more reports
that document its beneficiary properties. Although it is known that cannabis contains many similar
toxins and carcinogens to tobacco [111] and regular marijuana use has been shown to induce various
pulmonary problems [112,113], to date, there are no conclusive data associating it with an increased
risk of lung cancer [114,115].
Most reports on this subject have dealt with the benefits of cannabinoids in the control of
LC-induced pain and therapy side-effects [116]. However, the burden of evidence on the efficacy
of concurrent cannabis use with various cancer treatments is still not sufficiently strong to result in
official recommendations of their use in this setting. The interaction between the downstream effects of
approved chemo-, targeted and immunotherapy drugs for LC [106] and the metabolism of cannabinoids
is complex, which calls for caution in the interpretation of data derived from uncontrolled studies. Some
ECS components have shown a direct anti-cancer potential by modulating various signalling pathways
(ERK, PI3K, p38 MAPK, ceramide pathways), thus inducing apoptosis and/or the inhibition of cell
proliferation and epithelial-to-mesenchymal transition (EMT) [117]. Cannabinoid receptors CB1R
and CB2R have been shown to be over-expressed in LC at the genetic level, and this was associated
with prolonged survival of patients [117]. The agonist of CB2R JWH-015 was assessed in an in vivo
tumourigenesis model and had the ability to inhibit the EMT process of LC cells by down-regulating
EGFR signalling which is usually markedly increased in LC [118]. THC and CBD also suppressed
the basal EMT phenotype in vitro, by down-regulation of cadherin 1 (CDH1) and up-regulation of
cadherin 2 (CDH2) and vimentin (VIM). Synthetic cannabinoids WIN-55,212-2 and JWH-133 have
also been linked with the inhibition of growth and metastasis of LC cells in vitro and in vivo by
blockage of Akt phosphorylation and lowering the levels of matrix metalloproteinase-9 (MMP9) [119].
CBD-induced effects in LC cells have also been shown to be non-canonical, inducing the expression of
PPAR-γ and cyclooxygenase-2 (COX-2) [120]. PPARγ is a ligand-activated transcription factor that may
function as a tumour suppressor upon stimulation with cannabinoids in LC cells, through its ability to
regulate angiogenesis and production of matrix metalloproteinases in the LC microenvironment [121].
Activation of cannabinoid receptors can also selectively inhibit the lung-resident macrophages-induced
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release of angiogenic stimulators, thus modulating the complex process of vascular remodelling crucial
for cancer growth and inflammation [122].
2.6. Thyroid Cancer (TC)
Fewer than 1% of all thyroid nodules are cancerous and, even when they are, most of thyroid
cancers are very curable. In fact, the most common types of TC (papillary ~85%, follicular ~10%)
are most curable in patients younger than 50, with a 98% cure rate if treated appropriately. On the
other hand, there are rare forms such as anaplastic TC which are very aggressive (median survival
3–5 months) [123]. Even though these types of cancer are very rare (less than 2% of all thyroid cancers)
therapeutic options are needed for these aggressive forms of disease.
Even though there is a limited number of studies that investigated the effect of cannabinoids
on thyroid tumour development in vivo, some of them showed ECS’ involvement in tumour
growth modulation. It was reported that stimulation of CB1R by the endocannabinoid analog
2-methyl-arachidonyl-2′-fluoro-ethylamide (Met-F-AEA) inhibits the growth of rat TC cell-derived
tumour in athymic mice by inhibiting p21ras activity [124]. In addition, it was shown that Met-F-AEA
is also able to block the growth of already established tumours by inhibiting the expression of vascular
endothelial growth factor (VEGF) [125]. Since VEGF upregulation has been associated with malignancy
in human thyroid tumours and cancer cells [126] it is important to note that anandamide-based drugs
may be efficacious therapeutic drugs for the inhibition of cancer cell growth. Assuming that the
substances that inhibit the degradation of endocannabinoids should also be capable of inhibiting cancer
growth in vivo, the effect of endocannabinoid degradation inhibitors on the growth of rat thyroid
tumour xenografts induced in athymic mice was investigated [127]. It was shown that agents that
inhibited EMT (VDM-11) and blocked AEA hydrolysis (AA-5HT) prevented in vivo tumour growth.
Similarly, the endocannabinoid 2-AG reduced thyroid tumour development.
In the study by Shi et al., the synthetic cannabinoid JWH-133 was tested in the highly aggressive
anaplastic TC cell line ARO tumour model [128]. They investigated gene expression profiles of
ARO and ARO-IL/12 (cell line with lower tumourogenicity after interleukin (IL)-12 gene transfer) by
microarray analysis of 3757 genes. CB2R gene (CNR2) was expressed eightfold higher in ARO/IL-12
cells than ARO cells and at the same time was the most highly expressed gene in these experiments.
This was the study that demonstrated for the first time that CB2R expression is induced following
IL-12 expression in ARO cell line. The over-expression of CB2R makes cells more susceptibile to CB2R
agonist-mediated apoptosis and regression of tumours. Based on this assumption they further showed
that CB2R agonist JWH133 and mixed CB1R/CB2R agonist could induce a significantly higher rate
of apoptosis in ARO/IL-12 than ARO cells. Local administration of JWH133 showed a considerable
regression of thyroid tumours in nude mice generated by inoculation of ARO/CB2R cells. Furthermore
they demonstrated a significant increase in apoptosis in ARO/IL12 and ARO/CB2R cells following
incubation with 15 nM paclitaxel which showed senzitization of tumour cells to chemotherapy.
The results of these studies suggest that manipulation of the ECS can be consider as an option
to prevent propagation of thyroid tumour cells and that CB2R may be a therapeutic target for the
treatment of the most aggressive types of TC. We note that in vivo TC studies with cannabinoids are
scarce and more rigorous evaluation is needed to confirm the role of the ECS in this malignancy.
2.7. Central Nervous System Malignancies
There are over 130 types of brain tumours, as classified by the World Health Organisation. Brain
tumours can differ in the cells they originate from, how quickly they are likely to grow and spread,
and the location of the brain they affect. The most common types of adult brain tumours or gliomas
include glioblastoma, astrocytoma, meningioma and pituitary adenoma. Gliomas are defined as
the tumours that display histological, immunohistochemical, and ultrastructural evidence of glial
differentiation. They are classified according to cellular features and grade of malignancy [129].
Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most frequent class of malignant
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primary brain tumours being the most aggressive form of cancer. Consequently, survival after diagnosis
is low [129,130], due primarily to the high invasiveness and proliferation rate of GBM. Additionally,
GBM exhibits a high resistance to standard chemotherapy and radiotherapy. Current standard
therapeutic strategies for the treatment of GBM are only palliative including surgical resection and
focal radiotherapy [130,131]. It has been recently found that cannabinoids exert anti-glioma actions in
laboratory animals and constitute a potential cannabinoid-based therapy for GBM [132].
Most of our research on cannabinoid anti-tumoural action has focused on gliomas [133]. Glioma cells
have been used as the most common model system for studying cannabinoid-induced anticancer mechanisms.
Initial studies showed that cannabinoids can induce apoptosis of glioma cells via CB1R and CB2R dependent
de novo synthesis of the sphingolipid ceramide showing pro-apoptotic properties [47,94,134–137]. CB1R is
over-expressed in glioblastomas [138] and paediatric low-grade gliomas, and is implicated in tumour
involution induced by apoptosis and cell-cycle arrest upon activation [139]. CB2R is also highly expressed in
glioblastomas and astrocytomas and related to tumour grade [94,137,138,140,141]. While some authors have
observed that AEA levels are lower in gliomas, compared with non-tumour tissue [138,142], others have
detected higher levels of this endocannabinoid in gliomas and also in meningiomas [143]. Regarding
2-AG level, it was up-regulated in both brain tumour types [138,143]. Various authors have shown
that AEA inhibited in vitro proliferation of several glioma cells via induction of apoptosis [85,94,144,145].
It also decreased the migration and invasion of these cells [146,147]. In addition to AEA, 2-AG and other
endocannabinoids reduced the proliferation of C6 glioma cells [148] and these effects were mediated
by CBRs [149]. Cannabidiol and ∆9-THC, administered alone or in combination, have also displayed
an anti-proliferative effect on several glioma cell lines, inducing apoptosis, with the participation of
CB2R [94,150,151].
Animal model studies have shown that local administration of THC or WIN-55,212-2 reduced the
tumours formed by intracranial inoculation of C6 glioma cells. This led to eradication of gliomas and
increased survival in one third of treated rats [132,134]. Local administration of THC, WIN-55,212-2,
or JWH-133 also slowed down tumour growth derived from rat glioma C6 cells and GBM cells obtained
from patient tumour biopsies [132,134,137]. These and other studies also showed that activation of
cannabinoid receptors on glioma cells modulates important signalling pathways involved in cell
proliferation and survival. The downstream anti-cancer cannabinoid-induced events in gliomas have
not been elucidated in detail, but there is substantial evidence to confirm their role in apoptosis and
inhibition of angiogenesis [132]. Finally, cannabinoids have shown anti-tumour activity in brain cancer.
One of the first studies performed to evaluate cannabinoids’ antitumoural actions was performed
by Guzmán and collaborators, who showed that cannabinoids can inhibit tumour growth [47,133].
Due to ethical and legal issues, the first studies were conducted in terminal patients with recurrent
tumours [47,152]. These studies elaborated on their palliative effects, but also on their potential
anti-cancer effects, alone or in combination with other drugs. In 2017, a phase II, randomized,
placebo-controlled clinical trial with recurrent GBM patients was announced and showed the potential
efficacy of cannabinoids as add-on anticancer drugs. A combination of THC and CBD in addition to
dose-intensive temozolomide was tested. This study showed a significantly higher one-year survival
rate in the cannabinoid-treated group (83% vs. 53%), and the median survival was also longer
(550 days compared to 369 days) (GW Pharmaceuticals, 2017 press release; ClinicalTrials.gov Identifiers:
NCT01812616, NCT01812603).
2.8. Melanoma
Melanoma represents an aggressive form of malignant skin cancer which develops by
transformation of melanocytes. Despite the introduction of targeted therapies and immunotherapy for
the treatment of malignant melanoma, it is still associated with significant morbidity and mortality [59].
In order to improve the prognosis of these patients, repurposing of already approved drugs for other
uses has been suggested as a viable approach [153] as well as re-evaluation of targets, like the skin ECS,
that have shown benefit in other conditions and uses.
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In a recent study, a treatment of mice with CBD induced a significant decrease in tumour size
compared to placebo, and an increased survival and movement ability was also detected [154].
The activation of cannabinoid receptors on melanoma cells can lead to G1-cell cycle arrest by
the inhibition of Akt and pRb signalling molecules, activation of caspase-3, stimulation of ROS
production, and inhibition of the expression of EGF and VEGF, which in turn lowers the proliferation
and metastatic potential of melanoma cells [155]. CB2Rs is over-expressed in melanoma [156].
However, the complex interactions between the inflammatory component present in the skin tumour
microenvironment and the ECS can lead to various outcomes depending on the level of ECS activation
and the specific ECS component. The activation of CB2R by CBD can lead to anti-inflammatory
and immuno-modulatory effects, which in turn might regulate the overall response of melanoma
cells to therapy [154]. AEA, THC and synthetic cannabinoids WIN-55,212–2 and JWH-133 have also
shown some anti-cancer potential, acting through CB1R and CB2R [157,158]. The application of
the endocannabinoids AEA, 2-AG, as well as the endogenous signalling lipid PEA and inhibitor of
FAAH involved in ECS metabolism were shown to increase cell death both in vitro and in vivo [159].
On the contrary, reports of a pro-tumourigenic effect of CB1R also exist [160]. This further emphasizes
the interplay between the ECS, the specific cancer cell type and the immune microenvironment which
needs to be considered when designing future studies. The dose of the applied cannabinoid, as well as
its complex interaction with the primary anti-cancer therapy regimen via intersecting downstream
signalling pathways might have a significant impact on the final outcome [161,162].
3. Legal and Ethical Aspects of ECS Exploitation in Oncology
While clinical trials employing phytocannabinoids as CBD or targeting other components
of the ECS in cancer pose no more ethical issues than the ones that appear in almost every
human-related oncological clinical trial [163], medical, ethical and legal ramifications of the use
of exogenous psychotropic cannabinoids as THC are vast. Beside the favourable benefit-to-risk ratio,
fully autonomous and informed consent and careful monitoring for safety and side effects, additional
ethical considerations related to social context and lingering misconceptions are related to medicinal
cannabis use.
Cannabinoids have an important role in palliative medicine due to their analgesic and
antiemetic effects, but an increasing number of preclinical studies indicate their anticancer properties
as well. Even though some cannabinoid-based drugs have been registered in several countries
(e.g., nabiximols, dronabinol, nabilone), there have been studies demonstrating moderate- or
low-quality evidence supporting the use of these agents in anti-cancer treatment [164]. The ethical and
medical debates are still ongoing about the use of psychotropic cannabinoids as therapeutics in cancer
patients. The proof of profound safety and efficacy in clinical trials is lacking and it is hard to assess the
potential benefits and risks. Many aspects are still unknown about the way of administration, dosage,
interaction with other drugs and adverse effects. The legal prohibition of medical marijuana on the
other hand directly confronts the personal and autonomous freedom of choice. It might be said that
medical facts are still too vague to overturn the informed decision that harms are not inflicted to third
parties when marijuana is used for medicinal purpose and that possible harms cannot outweigh the
suffering that can probably be removed by the drugs [165]. The social and political history of cannabis
prohibition and the stigma it has perpetuated continues to stand in the way of detailed systematic
research that will help elucidate many dilemmas pertaining to its use. To help guide the research in
this exciting medical filed, the principles of biomedical ethics, i.e., respect for autonomy, beneficence,
and justice, should be followed.
4. Conclusions
The use of ECS components as anti-cancer agents and targets, and the range of effects they might
induce (cell death, regulation of angiogenesis and invasion or anticancer immunity), depend in great
deal on the specific cannabinoid ligand acting in a specific cancer cell type. Although an attractive
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target, the use of ECS components in anti-cancer treatment is interlinked with many legal and ethical
issues that need to be considered. The legislation which outlines the permissive boundaries of their
therapeutic use in oncology is still unable to follow the current scientific burden of evidence, but the
number of ongoing clinical trials might tip the scale forward in the near future.
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